About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
136
JPY
+12
(+9.68%)
Apr 10, 11:23 am JST
0.92
USD
Apr 9, 10:23 pm EDT
Result
PTS
outside of trading hours
135.9
Apr 10, 11:26 am JST
Summary Chart Historical News Financial Result
PER
PBR
1.25
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:06 am
139 JPY 0.94 USD
Previous Close Apr 9
124 JPY 0.85 USD
High Apr 10, 9:06 am
140 JPY 0.94 USD
Low Apr 10, 9:31 am
131 JPY 0.89 USD
Volume
163,600
Trading Value
0.02B JPY 0.15M USD
VWAP
136.23 JPY 0.93 USD
Minimum Trading Value
13,600 JPY 92 USD
Market Cap
5.89B JPY 0.04B USD
Number of Trades
172
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,082
1-Year High Jul 22, 2024
13,759
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 89,100 2,191,400 24.59
Mar 28, 2025 92,600 2,300,900 24.85
Mar 21, 2025 96,600 2,475,100 25.62
Mar 14, 2025 93,600 2,400,700 25.65
Mar 7, 2025 92,100 2,410,900 26.18
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.